Latest updates
Inhibikase makes a case for c-Abl
Research has suggested that in some cases of Parkinson’s a protein called c-Abl tyrosine kinase is abnormally over-active and this contributes to nerve cell...
Nicotinamide riboside for Parkinson’s: pilot results published
Researchers in Norway have published the promising results of a pilot clinical study of nicotinamide riboside for people with Parkinson's.
The PROSEEK trial of KO706
Sun Pharma Advanced Research Company (SPARC) is conducting a phase 2 clinical trial to evaluate the safety and effectiveness of its experimental c-Abl inhibitor...
Iron and the brain
Recent studies exploring iron levels in the brains of people with Parkinson's have shown important implications for its use as a biomarker, as well...
Rheumatoid arthritis and Parkinson’s
Recently, researchers have asked whether there is an association between Parkinson's and rheumatoid arthritis: Could people with rheumatoid arthritis be at higher risk of...